ZVSA
What one share of Zyversa Therapeutics holds
Pharmaceutical Preparations
Zyversa Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Profit | −$3.40 |
|---|---|
| Cash and investments | $0.04 |
| Book value | −$1.74 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$1,090 | — | — | — | — |
| 2024 | — | −$8.48 | — | — | — | — |
| 2025 | — | −$4.18 | — | — | — | −$1.53 |
Common questions about Zyversa Therapeutics
How much does one share of Zyversa Therapeutics earn?
Over the last 12 months, Zyversa Therapeutics lost $3.40 for each share.
Does Zyversa Therapeutics pay a dividend?
Zyversa Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Zyversa Therapeutics’s book value per share?
Zyversa Therapeutics’s book value is negative (−$1.74 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of March 31, 2026.
How much cash and debt does each share of Zyversa Therapeutics have?
Each share of Zyversa Therapeutics has $0.04 of cash and investments, as of March 31, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.